{"organizations": [], "uuid": "bfd94752524bea0f797c3aebed56f434d9504e40", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kyowa-kirin-ultragenyx-announce-cr/brief-kyowa-kirin-ultragenyx-announce-crysvita-receives-conditional-marketing-authorization-in-europe-for-the-treatment-of-xlinked-hypophosphatemia-in-children-idUSFWN1QD0U5", "country": "US", "domain_rank": 408, "title": "BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T15:09:00.000+02:00", "replies_count": 0, "uuid": "bfd94752524bea0f797c3aebed56f434d9504e40"}, "author": "", "url": "https://www.reuters.com/article/brief-kyowa-kirin-ultragenyx-announce-cr/brief-kyowa-kirin-ultragenyx-announce-crysvita-receives-conditional-marketing-authorization-in-europe-for-the-treatment-of-xlinked-hypophosphatemia-in-children-idUSFWN1QD0U5", "ord_in_thread": 0, "title": "BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children", "locations": [], "entities": {"persons": [{"name": "brief-kyowa kirin", "sentiment": "neutral"}], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "germany", "sentiment": "none"}], "organizations": [{"name": "kirin", "sentiment": "neutral"}, {"name": "kyowa kirin", "sentiment": "none"}, {"name": "hypophosphatemia in children reuters staff", "sentiment": "none"}, {"name": "ultragenyx pharmaceutical inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News  10 PM / in 8 minutes BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children Reuters Staff 1 Min Read Feb 23 (Reuters) - Ultragenyx Pharmaceutical Inc: * KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN * ULTRAGENYX PHARMACEUTICAL - ‍FIRST COMMERCIAL LAUNCH OF CRYSVITA IS EXPECTED TO TAKE PLACE IN GERMANY IN Q2 OF 2018​ Source text for Eikon:  ", "external_links": [], "published": "2018-02-23T15:09:00.000+02:00", "crawled": "2018-02-23T15:24:10.072+02:00", "highlightTitle": ""}